AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01439555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: L-Arginine, 2 Gm four times per day orally;
Study NCT01439555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: Tetrahydrobiopterin 20 mg/kg/day orally
Study NCT02655965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine 3.5 mg/ml
Study NCT02655965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 5µg/ml
Study NCT02655965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Sodium Chloride 0.9 %
Study NCT02244502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L(O)
Description: Patients will be treated continuously with the NovoTTF-100L(O). NovoTTF-100L(O) treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
Study NCT02244502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 over 1 hour infusion will be administered weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day cycle.
Study NCT02598375 — intervention group
Intervention type: OTHER
Intervention: Feeding intolerance
Description: In this study ; it is aimed to show the value of IFABP regarding the identifying the feeding intolerance and early detection of enteral feeding intolerance
Study NCT00542256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy
Description: 14 days of constraint induced movement therapy with 10 weekdays of up to 6 hours of training of the affected arm combined with application of tDCS over the primary motor cortex for 40 minutes.
Study NCT00542256 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy
Description: 14 days of constraint induced movement therapy with 10 days of up to 6 hours of training in the affected arm and sham tDCS applied over the primary motor cortex for 40 minutes with active current applied for 30 seconds.
Study NCT04227366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-089
Description: BCD-089 162 mg SC
Study NCT04227366 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04227366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexat
Description: 15 to 25 mg/week
Study NCT04227366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexat
Description: 15 to 25 mg/week
Study NCT03295162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Description: Melatonin will be given at a total dose of 20 mg dissolved in 4 ml of distilled water via enteral route in two doses of 10 mg each(2 ml ), with a 1-hour interval. to one group together with conventional treatment
Study NCT03295162 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional treatment of neonatal sepsis
Description: Conventional treatment of neonatal sepsis including antibiotics,IV fluids, Total Parenteral Nutrition,etc...
Study NCT03295162 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment of neonatal sepsis
Description: Conventional treatment of neonatal sepsis including antibiotics,IV fluids, Total Parenteral Nutrition,etc...
Study NCT02284126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Topically applied powder and paste to surgical site at time of closure.
Study NCT03473574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: immune checkpoint inhibitor
Study NCT03473574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: standard chemotherapy
Study NCT03473574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: standard chemotherapy
Study NCT03473574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: standard chemotherapy
Study NCT03473574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: standard chemotherapy
Study NCT03473574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: immune checkpoint inhibitor
Study NCT00000421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT00000421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00621478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorazepam or diazepam
Description: Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push.
Study NCT04117971 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The study will involve structured questionnaire asking questions about knowledge, attitude, and practice of child abuse diagnosis and reporting among dentists.
Study NCT00322283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oglemilast
Description: Oglemilast, 15mg once per day, oral administration
Study NCT00322283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-marched placebo, once per day, oral administration
Study NCT02253862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: administered days 1, 8 and 16
Study NCT03560856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fulvestrant + palbociclib
Description: Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
Study NCT00751595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tat protein
Description: Biologically active recombinant Tat protein
Study NCT03501667 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of decision support tool
Description: use of a decision support software during clinical assessment of a case
Study NCT03501667 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of UpToDate
Description: Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
Study NCT02410304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Xrays
Description: Clinical evaluation
Study NCT02410304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound (B mode )
Study NCT02410304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound (D mode)
Study NCT03092102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.
Study NCT02193399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy in patients with stem cell transplantation
Description: The exercises are repeated in both upper limbs and both lower limbs. All exercises are performed with specific respiratory exercises simultaneously the movement that takes place each year form.~The exercises are carried out by the physiotherapist applying in a passive way (ascending or descending) progressive strength and degree of difficulty and variables depending on the clinical condition of the patient.
Study NCT02011659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Study NCT03894670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard mixed breakfast meal
Description: The standard mixed breakfast meal consists of:~150 g yoghurt, 20 g muesli; 50 g wheat bun; 22 g rye bread; 25 g cheese; 25 g marmalade; 8 g butter; Total energy content: 500 kcal Macronutrient composition: 34 E% fat, 17 E% protein, 49 E% carbohydrate
Study NCT03894670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SmartBar™
Description: SmarBar™ (Medtronic, North Haven, MA, USA). Weight: 72 g; Total energy content: 260 kcal Macronutrient composition: 7 E% fat, 19 E% protein, 74 E% carbohydrate.
Study NCT01155362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Placenta-Derived Cells PDA001 Intravenous Infusion
Study NCT01155362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehice Control
Study NCT03366298 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Epipen 0.3mg
Description: Epipen 0.3mg auto-injector
Study NCT03366298 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Emerade 300mcg
Description: Emerade 300mcg auto-injector
Study NCT03366298 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Emerade 500mcg
Description: Emerade 500mcg auto-injector
Study NCT00268489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00268489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study NCT04389021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The VR goggles have a 2560×1440 5.5 (538ppi) fast-switching LCD screen with standard 60Hz refresh, overclocked 72Hz refresh, running Android 7.1.2 Nougat with a Quad-core Qualcomm Snapdragon 821 (two 2.3GHz Kryo HP cores and two 2.15GHz Kryo cores). Adreno 530 as GPU. It is 190 x 105 x 115 mm en weighs 470 g (1.04 lbs). The goggles have built-in speakers, a controller, proximity sensor, 3DOF sensors (both headset and controller).~Any pre-procedural self-administration of pain medication will be recorded. Trained staff-members or senior residents will do all IUD insertions, according to the local protocol.
Study NCT03095794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: How people learn another's value preference during decision under risk
Description: The aim of this study is to investigate how an agent learns another's value preference when they should make decisions on behalf of another. This experiment consists of 3 parts(i) measuring individual's loss aversion; (ii) feedback based learning of another's value preference; (iii) and decisions on behalf of others.
Study NCT03095794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mechanism of making a group decision under risk that influences on in-group members
Description: how individuals evaluate the risk and the outcome when they should make a single agreement decision in a group that will influence every member's payoff regardless of individuals' decisions. For the first part of the experiment, we will measure the individual level of loss aversion which will be used as the parameter for controlling individual differences.
Study NCT03095794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mechanism of making a group decision that influences on out-group members
Description: Human is decimated with other species by delegation of one responsibility. Although the person who has no-interests with the outcome of decision, they should make a delegated decision. Therefore, this decision has influences on others who are not part of the group. The third party punishment (Juries decision making) is one example of the decision made by a group influencing the out group members.
Study NCT03095794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: For neuroimaging passes, the expected duration of each of the experimental protocols is about 1h30 for tasks 1 and 2 and about 2h for task 3. The maximum period foreseen for neuroimaging tests is 3 years and will start as soon as possible. Completion of the behavioral tests.
Study NCT02025868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adherence reinforcement
Description: Directly observed treatment at home (family or relatives DOT); pillboxes; phone calls; SMS; home visits; adherence reinforcement sessions by trained health workers.
Study NCT02025868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)
Description: Second-line ART regimen : ongoing regimen at the time of inclusion will be continued.~Third-line ART regimen : Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)
Study NCT02230059 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
Study NCT00736255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Nicotine Patch
Description: All subjects will lreceive transdermal nicotine patch during beginning at Visit 0 (quit smoke date). The dose will be tapered down from 21 mg to 14mg after week 1,vthen to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.
Study NCT00736255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: All subjects will lreceive transdermal nicotine patch during beginning at Visit 0 (quit smoke date). The dose will be tapered down from 21 mg to 14mg after week 1,vthen to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.
Study NCT00736255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lis-dexamphetamine (Vyvanse)
Description: Subjects on this arm will receive Lis-dexamphetamine day after the identified quit date. All subject will start with 30mg once a day and will be titrated up to 50mg then to 70mg over a 3 week period to reach an optimized dose. They will then be maintained on this optimized dose until the 4th week.
Study NCT00736255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects on this arm will receive matching placebo, along with Nicotine Replacement Therapy.
Study NCT00633906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HORIZONS HIV Intervention
Description: Two-session, group-based interactive HIV prevention intervention
Study NCT00633906 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: enhanced standard-of-care
Description: 1 hour group session consisting of an HIV prevention video, a question and answer session with an African American woman health educator, and participation in a group discussion about how to avoid acquiring HIV.
Study NCT04125550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 2-3 mg/kg propofol will be administered for anesthesia induction. 10 mg/ kg/h propofol infusion will be administered for the maintenance of anesthesia.
Study NCT04125550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: sevoflurane inhalation (2-8%) will be administered for anesthesia induction. 2% sevoflurane inhalation will be administered for the maintenance of anesthesia.
Study NCT03652038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-8236
Description: Study drug to be administered via inhaler device
Study NCT03652038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered via inhaler device
Study NCT00407095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pardoprunox
Description: 12-42 mg/day
Study NCT01781715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting coronary stent
Description: Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
Study NCT01781715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-eluting coronary stent
Description: Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
Study NCT04058340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactizole nebulization
Description: Lactizole is generally recognized as safe: GRAS Flavor and Extract Manufacturers Association ( numer: 3773 ) Lactizole solution for nebulization was calculated based on dose-response curves; 150ppm was chosen as minimal effective (decreased sweet taste perception) and safety ( lack of FEV1 changes after nebulization)
Study NCT04058340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl solution in nebulization
Study NCT04225130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy -for Suicide
Description: The first session will consist of the therapist educating the participant about common reactions to trauma and providing information regarding the rationale of WET-S as a treatment for PTSD. The participant will then be given general instructions for completing the trauma narratives, specific instructions for completing the first session, and will then complete the first (30 minutes) narrative writing session. Participants will be instructed to write about the same trauma experience during each session. The importance of delving into their deepest emotions surrounding the trauma event is emphasized. All WET-S sessions will take place in a private room and begin with the therapist reading the specific writing instructions for that session and then leaving the instructions with the participant while 30-minute writing session is completed.
Study NCT04225130 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team (e.g., psychiatrists, therapists, case managers, behavioral health techs). TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
Study NCT01439282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Cohort I \& II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles
Study NCT01439282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
Study NCT01141504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PeakATP 250
Description: The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day
Study NCT01141504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules that are comparable in size and color to the active comparator for blinding purposes
Study NCT01141504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PeakATP 400
Description: The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day
Study NCT01141504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PeakATP 400 plus proprietary blend
Description: The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
Study NCT00350948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcyta
Description: Day 1 of 28 day Cycle.
Study NCT00350948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Doxorubicin
Description: Day 1 of 28 Day Cycle. 50 mg/m2
Study NCT00350948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Day 1 of 28 Day Cycle. 50 mg/m2
Study NCT01834092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma
Description: 2 Units of plasma transfused equvilant to 2 times 275ml
Study NCT01834092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma
Description: 2 Units of plasma transfused equvilant to 2 times 275ml
Study NCT03045770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil was used as first line treatment with AGC.
Study NCT03045770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin was used as first line treatment with AGC.
Study NCT03045770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was used as first line treatment with AGC.
Study NCT03045770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was used as first line treatment with AGC.
Study NCT03045770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium levofolinate
Description: Calcium levofolinate was used as first line treatment with AGC.
Study NCT01502709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caloric Vestibular Neurostimulation
Description: 1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear
Study NCT01502709 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo device
Study NCT04389762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: daily ingestion of Lactobacillus plantarum PS128
Description: daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)